Method of screening anti-mycobacterial molecules

a technology of mycobacterial molecules and anti-mycobacterial agents, which is applied in the field of screening anti-mycobacterial molecules, can solve the problems that the typical mycobacterial infection is often difficult to cur

Inactive Publication Date: 2003-08-21
JACKSON MARY +1
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

0008] We have characterized a new M. tuberculosis exported protein named DES, identified by using the PhoA gene fusion methodology. The des gene, which seems conserved among mycobacterial species, encodes an antigenic protein highly recognized by human sera from both tuberculosis and leprosy patients but not by sera from tuberculous cattle. The results of allelic exchange experiments described in this application, indicate that the des gene is essential to the survival of mycobacteria.

Problems solved by technology

Other mycobacteriosis caused by a typical mycobacteria such as M. avium, M. xenopi, and M. Kansasii also represent major health problems worldwide.
In addition, these a typical mycobacteriosis are often difficult to cure because of the lack of efficient drugs specifically directed against a typical mycobacteria.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method of screening anti-mycobacterial molecules
  • Method of screening anti-mycobacterial molecules
  • Method of screening anti-mycobacterial molecules

Examples

Experimental program
Comparison scheme
Effect test

examples

[0049] Bacteria, Media and Growth Conditions

[0050] The bacterial strains and plasmids used in this study are listed in FIG. 8. E. coli DH5a or BL21 (DE3) pLysS cultures were routinely grown in Luria B medium (Difco) at 37.degree. C. Mycobacterium cultures were grown in Middlebrook 7H9 medium (Difco) supplemented with Tween 0.05%, glycerol (0.2%) and ADC (glucose, 0.2%; BSA fraction V, 0.5%; and NaCl, 0.085%) at 37.degree. C. When required, antibiotics were added at the following concentrations: ampicillin (100 .mu.g / ml), kanamycin (20 .mu.g / ml).

[0051] Human and Cattle Sera

[0052] Serum specimens from 20 individuals with pulmonary or extra-pulmonary tuberculosis (M. tuberculosis infected) were obtained from the Bligny sanatorium (France). Six sera from M. bovis infected human tuberculous patients and 24 sera from BCG-vaccinated patients suffering from other pathologies were respectively obtained from Institut Pasteur, (Madagascar), and the Centre de Biologie Mdicale spcialise (CBMS) (...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
concentrationsaaaaaaaaaa
concentrationsaaaaaaaaaa
pHaaaaaaaaaa
Login to view more

Abstract

This invention relates to a novel mycobacterial protein named DES, which appears to share significant amino acid sequence homology with soluble stearoyl-ACP desaturases. The results of allelic exchange experiments, indicate that the des gene may be essential to the survival of mycobacteria. These results coupled with the surface localization, the unique structure of DES, and the fact this antigen is expressed in vivo, and DES protein induces a humoral response in human patients, indicate that the DES protein provides a new target for the design of anti-mycobacterial drugs. This invention provides methods of screening molecules that can inhibit the DES enzyme activity of purified DES protein, in order to identify antibiotic molecules that are capable of inhibiting the growth or survival of mycobacteria. These methods may be practiced by using recombinant DES protein obtained from a recombinant mycobacterium host cell that was transformed with a vector containing the des gene, whose expression is controlled by regulatory or promoter sequences that function in mycobacteria. Another aspect of this invention relates to the molecules that have been identified according to the screening methods as having antibiotic activity against mycobacteria.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001] This application hereby claims the benefit under 35 U.S.C. .sctn.119(e) of U.S. provisional applications S. No. 60 / 113,375, filed Nov. 4, 1998; S. No. 60 / 111,813, filed Dec. 11, 1998; and U.S. application Ser. No. 09 / 181,934, filed Oct. 28, 1998, which was converted to a provisional application under 37 C.F.R. .sctn.1.53(c)(2)on Jan. 14, 1999. The entire disclosure of each of these applications is relied upon and incorporated by reference herein.BACKGROUND OF THE INVENTION[0002] Tuberculosis and leprosy, caused by the bacilli from the Mycobacterium tuberculosis complex and M. leprae, respectively, are the two major mycobacterial diseases. Other mycobacteriosis caused by a typical mycobacteria such as M. avium, M. xenopi, and M. Kansasii also represent major health problems worldwide.[0003] M. avium is a predominant strain isolated from T.B. patients with AIDS (Horburgh et al., 1991) and M. xenopi along with M. kansasii and M. avium, is t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): C07K7/06C07K16/12C12N1/21C12Q1/18C12Q1/26
CPCC07K7/06C07K14/35C07K16/1289G01N2333/90245C12Q1/18C12Q1/26G01N2333/35C07K2319/21
Inventor JACKSON, MARYGICQUEL, BRIGITTE
Owner JACKSON MARY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products